# Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

> **NCT03564964** · — · NO_LONGER_AVAILABLE · sponsor: **Suven Life Sciences Limited**

## Conditions studied

- Alzheimer Disease
- Dementia
- Cognition Disorders

## Interventions

- **DRUG:** SUVN-502

## Key facts

- **NCT ID:** NCT03564964
- **Lead sponsor:** Suven Life Sciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564964, "Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03564964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*